Physician profile

Akram Kholoki

Cardiovascular Disease · Valparaiso, IN

NPI 1164598504

$11,262.01

in general payments reported to CMS, 2019-2025

48 companies · $1,659 in 2025

The $1,659 reported for 2025 was more than what 80% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$4,344.41

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novartis Pharmaceuticals Corporation $1,291.43 2019-2025
Astrazeneca Pharmaceuticals Lp $984.73 2019-2024 Farxiga, Brilinta
Merck Sharp & Dohme LLC $749.29 2021-2025 Verquvo
Medtronic, INC. $711.73 2021-2025 Symplicity G3, Heli-Fx Endoanchor System, Abre
Esperion Therapeutics, INC. $664.05 2020-2025 Nexletol
Boston Scientific Corporation $631.20 2019-2025 Watchman Flx
Janssen Pharmaceuticals, INC $583.27 2019-2024 Xarelto
E.R. Squibb & Sons, L.L.C. $513.53 2019-2025 Camzyos, Eliquis
Boehringer Ingelheim Pharmaceuticals, INC. $503.62 2019-2025 Jardiance
Pfizer INC. $373.26 2019-2025
Cardiovascular Systems INC. $348.82 2021-2022
Sanofi-Aventis U.S. LLC $335.65 2019-2023
Abiomed $322.78 2022-2025 Impella
Chiesi USA, INC. $309.17 2020-2021
Aop Health US, LLC $286.97 2025 Rapiblyk
Show all 48 companies
CompanyGeneral paymentsYearsTop products
Endologix LLC $264.86 2021-2022
Abbott Laboratories $258.68 2019-2025 Esprit
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $211.51 2019-2025 Lifevest
Amarin Pharma, INC. $179.20 2019-2022
Scpharmaceuticals INC. $171.81 2023-2025
Amgen INC. $169.19 2019-2025 Repatha, Repatha
Penumbra, INC. $146.17 2024 Indigo System
Bayer Healthcare Pharmaceuticals INC. $109.40 2021-2025
Astellas Pharma US INC $100.15 2022
Novo Nordisk INC $95.99 2025 Wegovy
Actelion Pharmaceuticals US, INC. $86.91 2022-2025 Uptravi, Opsumit
Kiniksa Pharmaceuticals International, Plc $85.41 2024 Arcalyst
Shockwave Medical, INC $74.03 2021-2024 Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter
Lundbeck LLC $67.10 2019
Biosense Webster, INC. $59.92 2019
Bard Peripheral Vascular, INC. $58.83 2019
Gilead Sciences, INC. $55.80 2019
Heartflow, INC. $55.62 2024-2025
Angiodynamics, INC. $54.02 2019-2021
Medtronic Vascular, INC. $44.25 2020
Kiniksa Pharmaceuticals, Ltd. $41.89 2021-2023 Arcalyst
Lexicon Pharmaceuticals, INC. $34.51 2024
Regeneron Healthcare Solutions, INC. $30.68 2019
Glaxosmithkline, LLC. $29.82 2025 Shingrix, Arexvy
Vifor Pharma, INC. $24.18 2019
Kestra Medical Technology Services, INC. $21.66 2025 Assure Wcd
Philips North America LLC $21.32 2020
Edwards Lifesciences Corporation $21.21 2020
W. L. Gore & Associates, INC. $20.53 2022
Bsn Medical INC $20.02 2019
Arbor Pharmaceuticals, INC. $13.42 2021
Ekos Corporation $12.57 2019
Kowa Pharmaceuticals America, INC. $11.85 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Akram Kholoki

$11,262.01

in general payments reported 2019-2025

Years
2019-2025
Top company
Novartis Pharmaceuticals Corporation
Context
The $1,659 reported for 2025 was more than what 80% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/7186/akram-kholoki

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.